Effectiveness of Intravenous Immunoglobulin for Management of Pain in Patients with Postpolio Syndrome

Table 1

Summary of the included studies.

#	First author, year	Study design	Number of patients (E/C)	Treatment compared with IVIG	IVIG protocol	Summary of the outcome
1	Gonzalez, 2006 [17]	RCT	142 (73/69)	Placebo	30 g3 days (repeated after 3 months)	No significant effect
2	Farbu, 2007 [18]	RCT	20 (10/10)	Placebo	2 g/kg for 2–4 days	At the 3-month follow-up, IVIG group > placebo group, IVIG group: VAS 4.5 (pretreatment) ⟶ 2.9 (3 months)
3	Werhagen, 2011 [10]	Single-arm prospective study	45	—	30 g3 days	After IVIG, VAS 5.3 (pretreatment) ⟶ 4.2 (6 months)
4	Gonzalez, 2012 [19]	RCT	41 (20/21)	Placebo	90 g (repeated after 3 months)	IVIG group > placebo group; after IVIG, VAS 3.1 (pretreatment) ⟶ 2.3 (1 year)
5	Bertolasi, 2013 [20]	RCT	50 (24/26)	Placebo	0.4 g/kg/day for 5 days	IVIG: VAS 5.4 (pretreatment) ⟶ 4.4 (2 months); placebo: VAS 4.9 (pretreatment) ⟶ 4.4 (2 months)

E: experimental group; C: comparison group; IVIG: intravenous immunoglobulin; RCT: randomized controlled trial; VAS: visual analogue scale.